BioSpace News Archive

KAHR, a cancer immunotherapy company developing novel multifunctional immuno-recruitment proteins, announced that the U.S. Food and Drug Administration has cleared its investigational new drug application for KAHR’s Phase 1b clinical trial of DSP107, a first-in-class CD47x41BB targeting fusion protein, in acute myeloid leukemia and myelodysplastic syndrome.

Samus Therapeutics, Inc., a privately held, Boston-based biopharmaceutical company developing epichaperome inhibitors to treat central nervous system diseases and hematologic malignancies, announced the publication of an open article in Nature Communications.

Cambium Biomaterials, the company creating high-performance biomaterials, announced a partnership with Ginkgo Bioworks, Inc., which is building the leading horizontal platform for cell programming.

Bausch Health Companies Inc. and its gastroenterology business, Salix Pharmaceuticals, one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, announced that new Health Economic Outcomes Research data featuring RELISTOR® will be shared at PAINWeek 2021 taking place in Las Vegas from Sept.

Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, announced that Craig Gibbs, Ph.D., Chief Executive Officer of Asher Bio, will participate in a fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Thursday, September 9, 2021 at 11:45 a.m. ET.

MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) (the “Company”), and BioXcel Therapeutics, Inc. (“BioXcel”), announce the publication of BioXcel’s International Patent Application No. PCT/US2020/051256 (published as WO2021055595) for detecting and preventing the early onset of agitation in patients predisposed to highly agitated behaviour.

Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced that Adagene’s Co-founder, Chief Executive Officer and Chairman, Peter Luo, Ph.D., will participate in the Morgan Stanley 19th Annual Global Healthcare Conference.

Cabaletta Bio, Inc., a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, announced that the Company will participate in two upcoming investor conferences in September:

Scout Bio announced that Mark Heffernan, Chief Executive Officer, will present at the upcoming Wells Fargo Virtual Healthcare Conference on Thursday, September 9, 2021 at 4:00 p.m. ET.

Quality treatment can be characterized as the expansion of totally new qualities inside the human cells.